<DOC>
	<DOCNO>NCT00003530</DOCNO>
	<brief_summary>RATIONALE : Antineoplastons naturally occur substance may also make laboratory . Antineoplastons may inhibit growth cancer cell . PURPOSE : This phase II trial study effectiveness antineoplaston therapy treat patient primary liver cancer .</brief_summary>
	<brief_title>Antineoplaston Therapy Treating Patients With Primary Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response , tolerance , side effect antineoplaston A10 patient incurable primary liver cancer . OUTLINE : This open label study . Patients receive gradually increase dos antineoplaston A10 arterial infusion daily final dose level reach . Therapy continue least 2 month absence unacceptable toxicity disease progression . Patients achieve complete response ( CR ) continue treatment additional 2 month reach CR . Tumors measure every month first 2 month , every 2 month first year , every 3 month second year . PROJECTED ACCRUAL : A total 20-40 patient accrue study .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary liver cancer unlikely respond exist therapy curative therapy exist Measurable disease CT scan MRI Tumor must least 2 cm PATIENT CHARACTERISTICS : Age : 14 Performance status : Karnofsky 60100 % Life expectancy : At least 2 month Hematopoietic : WBC least 2,000/mm3 Platelet count least 50,000/mm3 Hepatic : Bilirubin le 3 mg/dL SGOT/SGPT great 10 time upper limit normal No hepatic failure Renal : Creatinine great 2.5 mg/dL No history renal condition contraindicate high dos sodium Cardiovascular : No uncontrolled hypertension No known chronic heart failure No history congestive heart failure No history cardiovascular condition contraindicate high dos sodium Pulmonary : No serious lung disease ( e.g. , chronic obstructive pulmonary disease ) Other : Not pregnant nursing Fertile patient must use effective contraception 4 week study , study , 4 week study No serious medical psychiatric disease No active infection PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover No concurrent immunomodulating agent Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) recover No concurrent antineoplastic agent Endocrine therapy : Concurrent steroid allow Radiotherapy : At least 8 week since prior radiotherapy recover Surgery : Recovered prior surgery Other : No prior antineoplaston therapy Prior cytodifferentiating agent allow</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>stage IV childhood liver cancer</keyword>
	<keyword>recurrent childhood liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>